Management of atrial fibrillation in patients taking targeted cancer therapies

Cardio-Oncology

Volumn 3, Issue 1, 2017, Pages

  Asnani, Aarti ^a   Manning, Anastasia ^a   Mansour, Moussa ^a   Ruskin, Jeremy ^a   Hochberg, Ephraim P ^b   Ptaszek, Leon M ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

Author keywords

Anticoagulation; Atrial fibrillation; Cancer; Chemotherapy; Ibrutinib; Targed therapies

Indexed keywords

EID: 85048006616     PISSN: None     EISSN: 20573804     Source Type: Journal    
DOI: 10.1186/s40959-017-0021-y     Document Type: Review

References (38)

1. Hu YF, Liu CJ, Chang PM, Tsao HM, Lin YJ, Chang SL, Lo LW, Tuan TC, Li CH, Chao TF, et al. Incident thromboembolism and heart failure associated with new-onset atrial fibrillation in cancer patients. Int J Cardiol. 2013;165:355–7. DOI: 10.1016/j.ijcard.2012.08.036
2. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001;285:2370–5. DOI: 10.1001/jama.285.18.2370
3. Ostenfeld EB, Erichsen R, Pedersen L, Farkas DK, Weiss NS, Sorensen HT. Atrial fibrillation as a marker of occult cancer. PLoS One. 2014;9:e102861. DOI: 10.1371/journal.pone.0102861
4. Conen D, Wong JA, Sandhu RK, Cook NR, Lee IM, Buring JE, Albert CM. Risk of malignant cancer among women with New-onset atrial fibrillation. JAMA Cardiol. 2016;1:389–96. DOI: 10.1001/jamacardio.2016.0280
5. Rahman F, Ko D, Benjamin EJ. Association of atrial fibrillation and cancer. JAMA Cardiol. 2016;1:384–6. DOI: 10.1001/jamacardio.2016.0582
6. Onaitis M, D’Amico T, Zhao Y, O’Brien S, Harpole D. Risk factors for atrial fibrillation after lung cancer surgery: analysis of the Society of Thoracic Surgeons general thoracic surgery database. Ann Thorac Surg. 2010;90:368–74. DOI: 10.1016/j.athoracsur.2010.03.100
7. Nojiri T, Inoue M, Maeda H, Takeuchi Y, Sawabata N, Shintani Y, Yamamoto K, Okumura M. Low-dose human atrial natriuretic peptide for the prevention of postoperative cardiopulmonary complications in chronic obstructive pulmonary disease patients undergoing lung cancer surgery. Eur J Cardiothorac Surg. 2013;44:98–103. DOI: 10.1093/ejcts/ezs646
8. Imperatori A, Mariscalco G, Riganti G, Rotolo N, Conti V, Dominioni L. Atrial fibrillation after pulmonary lobectomy for lung cancer affects long-term survival in a prospective single-center study. J Cardiothorac Surg. 2012;7:4. DOI: 10.1186/1749-8090-7-4
9. DeSantis CE, Lin CC, Mariotto AB, Siegel RL, Stein KD, Kramer JL, Alteri R, Robbins AS, Jemal A. Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin. 2014;64:252–71. DOI: 10.3322/caac.21235
10. Chung MK, Martin DO, Sprecher D, Wazni O, Kanderian A, Carnes CA, Bauer JA, Tchou PJ, Niebauer MJ, Natale A, Van Wagoner DR. C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation. Circulation. 2001;104:2886–91. DOI: 10.1161/hc4901.101760
11. Bayraktar UD, Dufresne A, Bayraktar S, Purcell RR, Ajah OI. Esophageal cancer presenting with atrial fibrillation: a case report. J Med Case Rep. 2008;2:292. DOI: 10.1186/1752-1947-2-292
12. Holzhauser L, Heymer J, Kasner M, Landmesser U, Skurk C. Rare case of a multilocular primary cardiac intimal sarcoma presenting as left atrial mass with new onset atrial fibrillation. Eur Heart J. 2015;36:2402. DOI: 10.1093/eurheartj/ehv215
13. Cohen JE, Kogan J, Oren S, Mazza M. Primary cardiac lymphoma presenting with atrial fibrillation. Isr Med Assoc J. 2011;13:635–7.
14. Guglin M, Aljayeh M, Saiyad S, Ali R, Curtis AB. Introducing a new entity: chemotherapy-induced arrhythmia. Europace. 2009;11:1579–86. DOI: 10.1093/europace/eup300
15. National Cancer Institute, [https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies/targeted-therapies-fact-sheet]. Accessed 24 Jan 2017.
16. Byrd JC, O’Brien S, James DF. Ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369:1278–9. DOI: 10.1056/NEJMoa1215637
17. Advani RH, Buggy JJ, Sharman JP, Smith SM, Boyd TE, Grant B, Kolibaba KS, Furman RR, Rodriguez S, Chang BY, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol. 2013;31:88–94. DOI: 10.1200/JCO.2012.42.7906
18. Burger JA, Keating MJ, Wierda WG, Hartmann E, Hoellenriegel J, Rosin NY, de Weerdt I, Jeyakumar G, Ferrajoli A, Cardenas-Turanzas M, et al. Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study. Lancet Oncol. 2014;15:1090–9. DOI: 10.1016/S1470-2045(14)70335-3
19. O’Brien S, Furman RR, Coutre SE, Sharman JP, Burger JA, Blum KA, Grant B, Richards DA, Coleman M, Wierda WG, et al. Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial. Lancet Oncol. 2014;15:48–58. DOI: 10.1016/S1470-2045(13)70513-8
20. Byrd JC, Brown JR, O’Brien S, Barrientos JC, Kay NE, Reddy NM, Coutre S, Tam CS, Mulligan SP, Jaeger U, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014;371:213–23. DOI: 10.1056/NEJMoa1400376
21. Wang ML, Lee H, Chuang H, Wagner-Bartak N, Hagemeister F, Westin J, Fayad L, Samaniego F, Turturro F, Oki Y, et al. Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial. Lancet Oncol. 2016;17(1):48–56.
22. Thompson PA, Levy V, Tam CS, Al Nawakil C, Goudot FX, Quinquenel A, Ysebaert L, Michallet AS, Dilhuydy MS, Van Den Neste E, et al. Atrial fibrillation in CLL patients treated with ibrutinib. An international retrospective study. Br J Haematol. 2016;175(3):462–6. DOI: 10.1111/bjh.14324
23. Lipsky AH, Farooqui MZ, Tian X, Martyr S, Cullinane AM, Nghiem K, Sun C, Valdez J, Niemann CU, Herman SE, et al. Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib. Haematologica. 2015;100:1571–8. DOI: 10.3324/haematol.2015.126672
24. McMullen JR, Boey EJ, Ooi JY, Seymour JF, Keating MJ, Tam CS. Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling. Blood. 2014;124:3829–30. DOI: 10.1182/blood-2014-10-604272
25. Byrd JC, Harrington B, O’Brien S, Jones JA, Schuh A, Devereux S, Chaves J, Wierda WG, Awan FT, Brown JR, et al. Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374:323–32. DOI: 10.1056/NEJMoa1509981
26. Choueiri TK, Schutz FA, Je Y, Rosenberg JE, Bellmunt J. Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. J Clin Oncol. 2010;28:2280–5. DOI: 10.1200/JCO.2009.27.2757
27. Rose AJ, Sharman JP, Ozonoff A, Henault LE, Hylek EM. Effectiveness of warfarin among patients with cancer. J Gen Intern Med. 2007;22:997–1002. DOI: 10.1007/s11606-007-0228-y
28. Lee YJ, Park JK, Uhm JS, Kim JY, Pak HN, Lee MH, Sung JH, Joung B. Bleeding risk and major adverse events in patients with cancer on oral anticoagulation therapy. Int J Cardiol. 2016;203:372–8. DOI: 10.1016/j.ijcard.2015.10.166
29. Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, Rickles FR, Julian JA, Haley S, Kovacs MJ, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003;349:146–53. DOI: 10.1056/NEJMoa025313
30. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139–51. DOI: 10.1056/NEJMoa0905561
31. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883–91. DOI: 10.1056/NEJMoa1009638
32. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981–92. DOI: 10.1056/NEJMoa1107039
33. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, Waldo AL, Ezekowitz MD, Weitz JI, Spinar J, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369:2093–104. DOI: 10.1056/NEJMoa1310907
34. Wessler JD, Grip LT, Mendell J, Giugliano RP. The P-glycoprotein transport system and cardiovascular drugs. J Am Coll Cardiol. 2013;61:2495–502. DOI: 10.1016/j.jacc.2013.02.058
35. Stollberger C, Finsterer J. Relevance of P-glycoprotein in stroke prevention with dabigatran, rivaroxaban, and apixaban. Herz. 2015;40 (Suppl 2):140–5. DOI: 10.1007/s00059-014-4188-9
36. Gnoth MJ, Buetehorn U, Muenster U, Schwarz T, Sandmann S. In vitro and in vivo P-glycoprotein transport characteristics of rivaroxaban. J Pharmacol Exp Ther. 2011;338:372–80. DOI: 10.1124/jpet.111.180240
37. Zhang D, He K, Herbst JJ, Kolb J, Shou W, Wang L, Balimane PV, Han YH, Gan J, Frost CE, Humphreys WG. Characterization of efflux transporters involved in distribution and disposition of apixaban. Drug Metab Dispos. 2013;41:827–35. DOI: 10.1124/dmd.112.050260
38. Wang L, He K, Maxwell B, Grossman SJ, Tremaine LM, Humphreys WG, Zhang D. Tissue distribution and elimination of [14C]apixaban in rats. Drug Metab Dispos. 2011;39:256–64. DOI: 10.1124/dmd.110.036442